These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 14585913)

  • 1. Drug utilization review of celecoxib in Ontario.
    LeLorier J; Fitzsimon C; Keresteci M; Stewart D; Lavoie F
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii11-6. PubMed ID: 14585913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
    Rahme E; Hunsche E; Toubouti Y; Chabot I
    Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
    Wolfe F; Flowers N; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 May; 29(5):1015-22. PubMed ID: 12022317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
    Cox ER; Motheral B; Mager D
    Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
    Lee MC; Lee S; Suh DC; Kim J; Kong SX;
    Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
    You JH; Lee KK; Chan TY; Lau WH; Chan FK
    Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
    Sebaldt RJ; Petrie A; Goldsmith CH; Marentette MA
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):742-50. PubMed ID: 15623264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.
    Cryer B; Luo X; Assaf AR; Sands G; Mardekian J
    Curr Med Res Opin; 2011 Feb; 27(2):295-302. PubMed ID: 21142617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
    Wolfe F; Zhao S; Pettitt D
    J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
    Gibofsky A; Williams GW; McKenna F; Fort JG
    Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
    Moride Y; Ducruet T; Boivin JF; Lavoie F; Rochon S
    Can J Clin Pharmacol; 2005; 12(2):e201-11. PubMed ID: 15998959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec.
    Moride Y; Ducruet T; Rochon S; Lavoie F
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Celecoxib restrictions in medicare beneficiaries with arthritis.
    Louder AM; Joshi AV; Ball AT; Cappelleri JC; Deminski MC; Sanchez RJ
    Am J Manag Care; 2011; 17(7):503-12. PubMed ID: 21819170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
    Schnitzer TJ; Kong SX; Mitchell JH; Mavros P; Watson DJ; Pellissier JM; Straus WL
    Clin Ther; 2003 Dec; 25(12):3162-72. PubMed ID: 14749154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists.
    Greenberg JD; Bingham CO; Abramson SB; Reed G; Sebaldt RJ; Kremer J
    Arthritis Rheum; 2005 Feb; 53(1):12-7. PubMed ID: 15696570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.